[Abstract]The 2025 World Conference on Lung Cancer (WCLC) has recently concluded successfully. As the largest and most influential academic conference in the field of lung cancer diagnosis and treatment globally, this year's meeting presented long-term follow-up data from numerous key studies and exploratory results of novel treatment strategies. In the realm of targeted therapy, new-generation combination strategies have been established as a novel standard for first-line treatment in patients with advanced EGFR-mutant disease, significantly improving overall survival. Regarding immunotherapy, innovative combination regimens not only effectively address the challenge of resistance following EGFR-targeted therapy but also demonstrate clear long-term survival benefits in the perioperative setting and for patients with locally advanced disease, thereby informing new directions for treating earlier stages of non-small cell lung cancer. Substantial progress has been made with antibody-drug conjugates (ADCs), which have shown remarkable efficacy not only in patients with specific resistance mutations and those with brain metastases but also exhibit great potential for treating lung cancer patients with HER2 alterations and those with small cell lung cancer, offering new options for refractory cases. However, significant challenges remain, including the heterogeneity of resistance mechanisms, the selection of optimal treatment regimens, and therapeutic strategies for special populations. Future research must focus on exploring precise biomarkers and optimizing treatment strategies to comprehensively enhance clinical outcomes for lung cancer patients.
The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) was held from January 23 to 25, 2025. Several significant studies on the treatment of esophageal and gastroesophageal junction (GEJ) cancer were presented at the symposium, highlighting notable advances, particularly in the perioperative and advanced settings. Immunotherapy has demonstrated significant promise in the neoadjuvant treatment of esophageal cancer, showing potential to become a standard treatment. Furthermore, the long-term survival benefits of combining immunotherapy with chemotherapy for advanced GEJ cancer were further validated. This article summarizes and interprets the researches presented at the symposium concerning perioperative and advanced treatments for esophageal and GEJ cancers.
The 2025 European Lung Cancer Congress (ELCC) convened in Paris, France, centering on the optimization and innovation of immunotherapy for non-small cell lung cancer (NSCLC). Key topics at the congress included the application strategies for perioperative immunotherapy, breakthroughs in combination therapy models for advanced NSCLC, and the emerging roles of biomarkers in predicting diverse treatment outcomes. This paper integrates data from several key pivotal studies to systematically analyze the clinical value of neoadjuvant therapy within the perioperative setting, the potential of targeted combination regimens, and the challenges of managing drug resistance, thus offering new directions for clinical practice.
The 2024 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Annual Meeting, two of the most prestigious events in oncology, have concluded sequentially. As the most authoritative annual gatherings in lung cancer and the entire oncology field, the WCLC and ESMO conferences brought together top oncology experts and scientists from around the world to share, discuss, and publish the latest cutting-edge advancements in oncology. In both conferences, lung cancer immunotherapy remained a hot topic of considerable interest. This article aims to summarize and discuss the important research progress on perioperative immunotherapy for non-small cell lung cancer reported at the two conferences.
